Omipalisib

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameOmipalisib
Drug Alias Name奥帕利司Omipalisibum奥米利塞GSK-212GSK-458 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase beta inhibitorsPhosphatidylinositol 3 kinase delta inhibitorsPhosphatidylinositol 3 kinase gamma inhibitors +[6] 
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2Phosphatidylinositol 3 kinase beta +[6] 
Therapy Area/IndicationsSolid tumoursIdiopathic Pulmonary FibrosisNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsSolid tumoursIdiopathic Pulmonary FibrosisNeoplasms

Other Information

ATC CodeN/A
Related LinksKEGG